| Overall survival (5 years)b | Disease free survivalc(3 years) | ||
---|---|---|---|---|
HR (95% CI) | P values | HR (95% CI) | P values | |
Chemotherapy regimens | Â | Â | Â | Â |
 5-FU/ LV | Reference |  | Reference |  |
 Oxaliplatin plus 5-FU/LV | 0.55 (0.34,0.91) | 0.02 | 0.65 (0.41,1.05) | 0.08 |
 Oxaliplatin plus Capecitabine | 1.15 (0.42,3.16) | 0.79 | 1.07 (0.42,2.70) | 0.89 |
 Capecitabine Monotherapy | 0.80 (0.43,1.50) | 0.50 | 0.91 (0.50,1.64) | 0.75 |
 Mixed/Other | 0.89 (0.50,1.59) | 0.70 | 1.20 (0.70,2.05) | 0.51 |
Relative dose intensity | Â | Â | Â | Â |
 ≤70% | Reference |  | Reference |  |
 >70% | NAd |  | 0.75 (0.50,1.11) | 0.15 |
 At year 1 | 0.58 (0.37,0.89) | 0.01 |  |  |
 At year 2 | 0.74 (0.47,1.18) | 0.21 |  |  |
 At year 3 | 0.86 (0.52,1.44) | 0.57 |  |  |
 At year 4 | 0.96 (0.54,1.68) | 0.88 |  |  |
 At year 5 | 1.04 (0.56,1.91) | 0.90 |  |  |
 Unknown or Missing | 0.95 (0.51,1.78) | 0.88 | 0.97 (0.53,1.77) | 0.91 |
Age (years) | Â | Â | Â | Â |
 <55 | 0.68 (0.30, 1.52) | 0.34 | 1.00 (0.50, 1.97) | 0.99 |
 55-64 | Reference |  | Reference |  |
 65-74 | 0.99 (0.61,1.62) | 0.96 | 1.14 (0.72,1.82) | 0.57 |
 75+ | 2.06 (1.25,3.40) | 0.005 | 1.98 1.21,3.23) | 0.006 |
Male | 1.70 (0.39,7.52) | 0.48 | 1.67 (0.39,7.27) | 0.49 |
Race/Ethnicity | Â | Â | Â | Â |
 White (non-Hispanic) | Reference |  | Reference |  |
 Hispanic | 0.56 (0.17,1.80) | 0.33 | 0.27 (0.08,0.93) | 0.04 |
 Black (non-Hispanic) | 0.75 (0.37,1.50) | 0.41 | 0.76 (0.40,1.44) | 0.40 |
 Other/Missing | 1.42 (0.58,3.48) | 0.44 | 1.35 (0.59,3.11) | 0.48 |
Charlson Comorbidity Index (per unit) | 1.17 (1.06,1.30) | 0.002 | 1.15 (1.04,1.27) | 0.007 |
Married | 0.66 (0.45,0.97) | 0.03 | 0.86 (0.59,1.24) | 0.42 |
Tumor | Â | Â | Â | Â |
 T1/T2e | Reference |  | Reference |  |
 T3 | 1.62 (0.83,3.14) | 0.15 | 1.63 (0.88,3.02) | 0.12 |
 T4 | 5.88 (2.69,12.9) | <0.001 | 5.84 (2.82,12.1) | <0.001 |
Node | Â | Â | Â | Â |
 N1 | Reference |  | Reference |  |
 N2 | 1.68 (1.12,2.50) | 0.01 | 1.89 (1.30,2.77) | 0.001 |
Lymphovascular invasion | Â | Â | Â | Â |
 No | Reference |  | Reference |  |
 Yes | 1.69 (0.90,3.17) | 0.10 | 1.95 (1.10,3.45) | 0.02 |
 Unknown or Missing | 1.09 (0.57,2.07) | 0.79 | 1.20 (0.66,2.16) | 0.55 |
Bowel obstruction | Â | Â | Â | Â |
 No | Reference |  | Reference |  |
 Yes | 2.32 (1.36,3.95) | 0.002 | 2.12 (1.28,3.51) | 0.003 |
 Unknown or Missing | 1.05 (0.57,1.95) | 0.88 | 1.19 (0.67,2.10) | 0.56 |
Days between surgery and start of chemotherapy | Â | Â | Â | Â |
 ≤30 | Reference |  | Reference |  |
 31-60 | 1.44 (0.40,5.22) | 0.58 | 1.14 (0.37,3.49) | 0.82 |
 61-90 | 1.65 (0.43,6.25) | 0.47 | 1.35 (0.42,4.33) | 0.61 |
 91-120 | 1.84 (0.46,7.41) | 0.39 | 1.56 (0.46,5.32) | 0.47 |